Issues
-
Cover Image
Cover Image
TF-011-MMAE (HuMax-TF-ADC), an antibody-drug conjugate composed of a tissue factor-specific antibody, a protease-cleavable linker, and the microtubule disrupting agent monomethyl auristatin E, is a novel antitumor agent with promise as a broad-acting therapeutic in many types of human cancer. The antitumor activity of TF-011-MMAE is dependent on binding to tissue factor-positive tumor cells, followed by highly efficient internalization and lysosomal targeting, which allows intracellular release of the auristatin and subsequent tumor cell killing. After three hours of incubation with tissue factor-expressing ovarian cancer cells, TF-011 (green), the antibody backbone of TF-011-MMAE, colocalized with the lysosomal marker LAMP-1 (red). Colocalization of TF-011 and LAMP-1 (yellow) demonstrates that, upon target binding, TF-011 is rapidly targeted to the lysosomal compartment. For details, see article by Breij and colleagues on page 1214. - PDF Icon PDF LinkTable of Contents
Cancer Research
Table of Contents
Breaking Advances
Review
Priority Report
Microenvironment and Immunology
Oligodendrocyte Progenitor Cells Promote Neovascularization in Glioma by Disrupting the Blood–Brain Barrier
PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen–Specific CD8+ T Cells Induced by Melanoma Vaccines
Molecular and Cellular Pathobiology
Inducible Nitric Oxide Synthase Drives mTOR Pathway Activation and Proliferation of Human Melanoma by Reversible Nitrosylation of TSC2
Activation of the NOTCH Pathway in Head and Neck Cancer
HuR Posttranscriptionally Regulates WEE1: Implications for the DNA Damage Response in Pancreatic Cancer Cells
Cyclin E1 Deregulation Occurs Early in Secretory Cell Transformation to Promote Formation of Fallopian Tube–Derived High-Grade Serous Ovarian Cancers
Therapeutics, Targets, and Chemical Biology
The Niacin/Butyrate Receptor GPR109A Suppresses Mammary Tumorigenesis by Inhibiting Cell Survival
A Preclinical Model of CD38-Pretargeted Radioimmunotherapy for Plasma Cell Malignancies
Unbiased Compound Screening Identifies Unexpected Drug Sensitivities and Novel Treatment Options for Gastrointestinal Stromal Tumors
An Antibody–Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors
Tumor and Stem Cell Biology
Tumor Suppressor Alterations Cooperate to Drive Aggressive Mesotheliomas with Enriched Cancer Stem Cells via a p53–miR-34a–c-Met Axis
High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development
Correction
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.